These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 346616)

  • 1. Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia.
    Feldman EB; Gluck FB; Carter AC
    J Clin Pharmacol; 1978; 18(5-6):241-8. PubMed ID: 346616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of halofenate (MK-185) and clofibrate on plasma lipid and uric acid concentration in hyperlipoproteinemic patients.
    Lisch HJ; Patsch J; Sailer S; Braunsteiner H
    Atherosclerosis; 1975; 21(3):391-9. PubMed ID: 1148032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabolic spectrum of halofenate.
    Ryan JR
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):239-43. PubMed ID: 51838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year trials with halofenate, clofibrate, and placebo.
    Dujovne CA; Azarnoff DL; Huffman DH; Pentikäinen P; Hurwitz A; Shoeman DW
    Clin Pharmacol Ther; 1976 Mar; 19(3):352-9. PubMed ID: 177242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia.
    Krut LH; Seftel HC; Joffe BI
    S Afr Med J; 1977 Mar; 51(11):348-52. PubMed ID: 323994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A two-year crossover therapeutic trial with halofenate and clofibrate.
    Dujovne CA; Azarnoff DL; Pentikainen P; Manion C; Hurwitz A; Hassanein K
    Am J Med Sci; 1976; 272(3):277-84. PubMed ID: 797258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of hypoglycemic effect of sulfonylureas by halofenate.
    Jain AK; Ryan JR; McMahon FG
    N Engl J Med; 1975 Dec; 293(25):1283-6. PubMed ID: 171574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Halofenate in the treatment of type II hyperlipoproteinemia. Double blind comparison with clofibrate.
    Rees ED; Hamilton RD; Kanner IF; Wasson S; Hearn T
    Atherosclerosis; 1976 Sep; 24(3):537-46. PubMed ID: 788722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind comparison of the hypolipidemic and hypouricemic action of halofenate and clofibrate in patients with hyperlipoproteinemia (types III, IV and V).
    Neuman J; de Neuman MP; Talmasky S; Pesce R; Valero E; Martiarena JL
    J Cardiovasc Surg (Torino); 1973; Spec No():532-7. PubMed ID: 4377715
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate].
    Keller C; Wolfram G; Zöllner N
    Arzneimittelforschung; 1976; 26(12):2221-4. PubMed ID: 798591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of halofenate and probenecid on serum lipids and uric acid in hyperlipidemic, hyperuricemic adults.
    Bassett DR; Mikkelsen WM; Buckingham RB; Block WD; Sidiq M; Shakibai A; DiGaetano R; Liou LL
    Clin Pharmacol Ther; 1977 Sep; 22(3):340-51. PubMed ID: 330079
    [No Abstract]   [Full Text] [Related]  

  • 12. Halofenate: an effective hypolipemia- and hypouricemia-inducing drug.
    Aronow WS; Vangrow JS; Nelson WH; Pagano J; Papageorge's NP; Khursheed M; Harding PR; Khemka M
    Curr Ther Res Clin Exp; 1973 Dec; 15(12):902-6. PubMed ID: 4203573
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.
    Ferrari C; Frezzati S; Romussi M; Bertazzoni A; Testori GP; Antonini S; Paracchi A
    Metabolism; 1977 Feb; 26(2):129-39. PubMed ID: 834147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of halofenate on triglyceride and uric acid levels, coagulation and platelet behaviour in patients with hyperlipoproteinemia type IV and hyperuricemia (author's transl)].
    Kuntzen O; Hehl FJ; Walter E; Zimmermann R
    Arzneimittelforschung; 1978; 28(12):2349-52. PubMed ID: 227420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of halofenate on serum uric acid.
    Aronow WS; Harding PR; Khursheed M; Vangrow JS; Papageorge's NP
    Clin Pharmacol Ther; 1973; 14(3):371-3. PubMed ID: 4572799
    [No Abstract]   [Full Text] [Related]  

  • 16. Studies on the mechanism of action of halofenate.
    Mandel LR
    Lipids; 1977 Jan; 12(1):34-43. PubMed ID: 319318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered insulin and glucagon secretion in treated genetic hyperlipemia: a mechanism of theraphy?
    Eaton RP; Oase R; Schade DS
    Metabolism; 1976 Mar; 25(3):245-9. PubMed ID: 1250161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic triglyceride lipases--effect of clofibrate and halofenate.
    Cenedella RJ
    Biochem Pharmacol; 1976 Dec; 25(23):2657-61. PubMed ID: 10929
    [No Abstract]   [Full Text] [Related]  

  • 19. The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia.
    Hutchison JC; Wilkinson WH
    Atherosclerosis; 1973; 18(3):353-62. PubMed ID: 4584481
    [No Abstract]   [Full Text] [Related]  

  • 20. Potentiation of hypoglycemic effect of chlorpropamide and phenfromin by halofenate.
    Kudzma DJ; Friedberg SJ
    Diabetes; 1977 Apr; 26(4):291-5. PubMed ID: 321288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.